SWOG clinical trial number
SWOG-8949

A Randomized Comparison of Nephrectomy Followed by Interferon Alpha 2-b (Intron-A) vs. Interferon Alpha 2-b (Intron-A) Alone in Patients with Advanced Renal Cell Carcinoma

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
Renal
Activated
03/01/1991
Closed
10/01/1998

Research committees

Genitourinary Cancer

Treatment

Surgery Interferon alpha-2b

Publication Information Expand/Collapse

2019

Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research

C Ryan Urologic Oncology: Seminars and Original Investigations, May;37(5):318-323; Jul 31 [Epub ahead of print]

PMid: PMID30072304

Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

HL Kim;E Mayerson;E Messing;C Tangen;B Shuch;U Vaishampayan European Urology Focus; May 15 [Epub ahead of print]

PMid: PMID31103605 | PMC number: PMC6858992

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2014

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2009

Predictors of survival in advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 [PMID19100570; PMC3394523]

PN Lara;CM Tangen;S Conlon;RC Flanigan;ED Crawford Journal of Urology 181(2):512-516

2008

Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949

S Conlon;CM Tangen;RC Flanigan;ED Crawford Journal of Clinical Oncology 26(15S):260s, #5042

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group Trial S8949

S Conlon;C Tangen;RC Flanigan;ED Crawford;PN Lara American Society of Clinical Oncology Genitourinary Cancers Symposium, abst. 347

2004

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

RC Flanigan;G Mickisch;R Sylvester;C Tangen;H Van Poppel;ED Crawford Journal of Urology 171:1071-1076

2002

The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy

RA Gatenby;ET Gawlinski;CM Tangen;RC Flanigan;ED Crawford Cancer Research 62:5218-5222

2001

Nephrectomy followed by interferon alfa 2-b compared with interferon alfa-2b alone for metastatic renal-cell cancer

RC Flanigan;SE Salmon;BA Blumenstein;SI Bearman;V Roy;PC McGrath;JR Caton, Jr;N Munshi;ED Crawford New England Journal of Medicine 345(23):1655-1659

2000

Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949

RC Flanigan;BA Blumenstein;S Salmon;SI Bearman;V Roy;SP Balcerzak;PC McGrath;JR Caton;B Barlogie;ED Crawford Journal of Urology 163(4)Suppl:154

Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949

RC Flanigan;BA Blumenstein;S Salmon;ED Crawford Proc of the American Society of Clinical Oncology 19:2a(#3)

Other Clinical Trials

SWOG Clinical Trial Number
S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
5%
Open
Phase
III
SWOG Clinical Trial Number
S1802
SWOG Clinical Trial Number
CTSU/EA8153